Article Text

Download PDFPDF

284 A novel hybrid T-cell receptor form of CAR-T cells showed enhanced activity against solid tumors
  1. Meiou Liu,
  2. Yasushi Akahori,
  3. Hiroshi Fujiwara and
  4. Yoshihiro Miyahara
  1. Mie University Graduate School of Medicine, TSU, MIE, Japan
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Tumor-associated antigens (TAAs) have been attractive targets for immunotherapy. Current chimeric antigen receptor T cell (CAR-T) therapy can target TAA molecules expressed on the cell surface. However, a large proportion of TAA is expressed intracellularly, which cannot be recognized by conventional CAR-T cells. To overcome this obstacle, we have recently established a novel CAR utilizing a single-chain variable fragment (scFv) antibody which recognizes MAGE-A4-derived peptide/HLA-A*02:01 complex, enabling to target the intracellular tumor-specific antigen MAGE-A4. However, there is a substantial need to explore for more functional CAR structures. Therefore, we further designed a novel CAR (Hybrid-TCR) in which constant regions of TCR beta and alpha fused with VH and VL domains of the scFv antibody, respectively. In this study, we tried to investigate whether peptide/MHC-specific Hybrid-TCR cells could show further enhanced functions in vitro and in vivo compared with conventional CAR-T cells

Methods Both CAR and Hybrid-TCR T cells can specifically recognize MAGE-A4 (230–239) peptide (GVYDGREHTV) presented by HLA-A*02:01 by utilizing the same scFv antibody as an antigen receptor domain. To compare the in vitro functions, MAGE-A4 CAR or Hybrid-TCR T cells were co-cultured with SK-MEL-37 (A2+, MAGE-A4+) or HCT116(A2+, MAGE-A4-) cell line. Cytotoxic function was assessed after 3 hours co-cultivation, and cytokine secretion was evaluated after 24hours co-cultivation. For In vivo experiments, we used a tumor-bearing immunodeficient NOG mice model in which NW-MEL-38 (A2+, MAGE-A4+) cells were inoculated on their back. CAR or Hybrid-TCR cells were injected intravenously on day 4 after tumor inoculation.

Results Although the molecule expression level of CAR T cells is much higher than that of Hybrid-TCR cells, Hybrid-TCR cells show stronger efficacies of anti-tumor functions in vitro and in vivo. Particularly, adoptive transfer of Hybrid-TCR cells significantly suppressed the growth of NW-MEL-38 tumor. Of note, Hybrid-TCR cells showed minimal activation (tonic signaling) induced by antigen-independent clustering of the CAR receptor compared to the conventional CAR-T cells.

Conclusions We observed that a new form of CAR (Hybrid-TCR) has improved the efficacies of anti-tumor functions in vitro and in vivo compared with a conventional form of CAR. Further studies focused on these superior functions of Hybrid-TCR cells are under investigation.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.